Характеристики и методы лечения основных нежелательных явлений у пациентов с распространенным почечно-клеточным раком, получающих терапию комбинацией ленватиниба с пембролизумабом на основании результатов исследования CLEAR [PDF]
, 2023 .Введение. Комбинация ленватиниба с пембролизумабом продемонстрировала значительное улучшение показателей выживаемости без прогрессирования и общей выживаемости у пациентов с распространенным почечно-клеточным раком по сравнению с сунитинибом в ...
J. Puente +17 more
core +2 more sources
Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice [PDF]
, 2018 Aim. To assess the efficacy and tolerance of certolizumab pegol (CP) in patients with Crohn's disease (CD) treated in the Department of inflammatory bowel diseases of the A.S.
A A Lishchinskaya +6 more
core +1 more source
Personalized medicine in the treatment of inflammatory bowel diseases [PDF]
, 2018 Personalized medicine (personalized medicine, individualized medicine) represents the totality of methods of prevention of a pathological condition, diagnosis and treatment in the event of its occurrence, based on individual patient characteristics. Such
A I Parfenov +3 more
core +1 more source
University Therapeutic JournalВведение. Воспалительные заболевания кишечника включают в себя язвенный колит (ЯК) и болезнь Крона (БК), этиология которых на сегодняшний день не до конца установлена.
Наталья Николаевна Федосеева +2 more
doaj +1 more source
Региональная адаптация федеральной модели оплаты медицинской помощи по клинико-статистическим группам на примере случаев госпитализации пациентов, требующих назначения генно-инженерных биологических препаратов [PDF]
, 2018 The existing model of financial support of medical assistance for clinical-statistical groups (CSGs) in 2018 provides for the reimbursement for hospital stay expenses by the compulsory medical insurance fund in patients claiming the need for genetically ...
A. Khudyaev S. +15 more
core +2 more sources
Persistence of biologic therapy in patients with inflammatory bowel diseases in the Chelyabinsk region [PDF]
Aim. To assess the survival and reasons for discontinuation of genetically engineered biological therapy (GEBT) in patients with inflammatory bowel disease (IBD) in the Chelyabinsk region. Materials and methods.
Ajman S. Sarsenbaeva +9 more
core +2 more sources
Фармакоэкономический анализ применения лекарственного препарата белимумаб на фоне стандартной терапии системной красной волчанки [PDF]
, 2018 The aim is to study the clinical and economic aspects of using belimumab for the treatment of systemic lupus erythematosus (SLe) in patients with high SLe activity, the presence of anti-DNA, a low level of complement in the blood plasma and minimal lupus
A. G. Tolkushin +3 more
core +2 more sources
, 2021 Background: The analysis of data obtained from real world clinical practice of management of patients with inflammatory bowel diseases (IBD) is an effective tool to improve medical care for this patient category.
Abdulganieva D.I. +10 more
core +1 more source
Inflammatory Bowel Diseases in Children: Modern Achievements in Diagnostics and Therapy [PDF]
Aim: to highlight current trends in the diagnosis and treatment of inflammatory bowel diseases in children.Key points. The incidence of inflammatory bowel disease among children has increased significantly over the past three decades.
A. I. Khavkin +2 more
core +2 more sources
The relationship between clinical, biochemical and immune parameters of atherosclerosis as predictors of cardiovascular risk in patients with ulcerative colitis [PDF]
, 2023 Uvod i ciljevi: Ateroskleroza (AT) je jedna od najznačajnijih kardiovaskularnih manifestacija ulceroznog kolitisa (UK). Istraživanje je imalo za cilj da ispita poveznost kliničkih, biohemijskih i imunskih parametara AT, kao prediktora kardiovaskularnog ...
Lugonja, Sofija
core